People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aviceda Therapeutics, Inc. | — | Biotechnology | Series D+ | $173.6M | $706.3M | 2024 |
| Lux Biosciences Inc | — | Biotechnology | Series B | $81.1M | $635.0M | 2009 |
| Link Medicine Corp | — | Biotechnology | Series B | $64.8M | $190.8M | 2008 |
| Neovista Inc | — | Other Health Care | Series B | $63.3M | $114.9M | 2009 |
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2010 |
| Ophthotech Corp. | — | Biotechnology | Series B | $43.1M | $452.5M | 2018 |
| Sound Pharmaceuticals Inc | — | Biotechnology | Series A | $21.6M | $304.0M | 2018 |
| Invectys, Inc. | — | Biotechnology | Seed | $4.0M | $16.9M | 2024 |
David Guyer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Guyer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Dyrberg | 3 | 5 |
| Michael Ross | 2 | 18 |
| Lutz Giebel | 2 | 6 |
| Axel Bolte | 2 | 6 |
| William Link | 1 | 11 |
| David Neafus | 1 | 7 |
| Ryan Schwarz | 1 | 7 |
| David Schnell | 1 | 7 |
| ABBIE CELNIKER | 1 | 6 |
| William Greene | 1 | 6 |
| Colin Goddard | 1 | 5 |
| Stephen Martin | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| Robert Kniaz | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Steven Waite | 1 | 4 |
| Patrick Johnson | 1 | 4 |
| Steve Martin | 1 | 4 |
| James C. Towne | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.